|
Status |
Public on Mar 24, 2016 |
Title |
2_after |
Sample type |
RNA |
|
|
Source name |
2_after_R
|
Organism |
Homo sapiens |
Characteristics |
tissue: breast cancer tissue patient: 2 time point: after neoadjuvant chemotherapy
|
Treatment protocol |
All patients received epirubicin (75 mg/m2)–cyclophosphamide (750 mg/m2) intravenously every 3 weeks for four cycles followed by docetaxel (100 mg/m2) every 3 weeks for four cycles. We selected patients for who both biopsy and tumorectomy tissues were available. Surgery (lumpectomy or modified radical mastectomy associated to axillary clearance) was performed 21–45 days after cycle 8, according to initial and post-chemotherapy assessment
|
Extracted molecule |
total RNA |
Extraction protocol |
Qiazol extraction followed Qiagen miRNeasy protocol
|
Label |
Biotin
|
Label protocol |
100ng of total RNA was amplified by the Ambion® WT expression kit (ref 4411974) to generate cDNA sense target. Then products were labeled (biotinylated) using Affymetrix WT terminal labelling kit (ref 901524)
|
|
|
Hybridization protocol |
Following fragmentation, 5.5 ug of cDNA were hybridized for 17 hours at 45°C on Human Gene 1.1ST array plates. GeneChips were washed and stained in the Affymetrix® GeneTitan device.
|
Scan protocol |
GeneChip were scanned by Affymetrix® GeneTitan.
|
Description |
Gene expression of patient 2 after neoadjuvant chemotherapy
|
Data processing |
The data were analyzed with Partek Genomics Suite version 6.6. Normalization was performed using RMA bacground correction with pre-background adjustment for GC content.
|
|
|
Submission date |
Jan 28, 2013 |
Last update date |
Mar 24, 2016 |
Contact name |
Fatima Mechta-Grigoriou |
E-mail(s) |
fatima.mechta-grigoriou@curie.fr
|
Phone |
+33156246653
|
Fax |
+33156246650
|
Organization name |
Institut Curie
|
Department |
INSERM U830
|
Lab |
"Stress and Cancer" Lab.
|
Street address |
26 rue d'Ulm
|
City |
PARIS |
ZIP/Postal code |
75248 |
Country |
France |
|
|
Platform ID |
GPL11532 |
Series (1) |
GSE43816 |
Response to Neoadjuvant Chemotherapy in Triple Negative Breast tumors. |
|